| Literature DB >> 32558266 |
Cang-Long Hou1, Bo Li1, Ya-Jun Cheng1, Ming Li1, Zong-de Yang1.
Abstract
OBJECTIVE: To explore the molecular regulatory mechanisms underlying fibroblast differentiation and dysfunction in the development of adolescent idiopathic scoliosis (AIS) in an effort to identify candidate therapeutic targets for AIS.Entities:
Keywords: Adolescent idiopathic scoliosis; Differentially expressed genes; PRKG1; cGMP-PKG signaling pathway
Year: 2020 PMID: 32558266 PMCID: PMC7454216 DOI: 10.1111/os.12694
Source DB: PubMed Journal: Orthop Surg ISSN: 1757-7853 Impact factor: 2.071
Fig 1Schematic representation of the study design
The forward and reverse primers of genes and GAPDH normalizer for RT‐PCR
| Primer | Direction | Sequence (5′‐3′) |
|---|---|---|
| MAP2K1 | Forward | CAATGGCGGTGTGGTGTTC |
| Reverse | GATTGCGGGTTTGATCTCCAG | |
| PRKG1 | Forward | GACAACGATGAACCACCAC |
| Reverse | GCTTTGCTTCAGGACCAC | |
| DUSP6 | Forward | GAAATGGCGATCAGCAAGACG |
| Reverse | CGACGACTCGTATAGCTCCTG | |
| KAT2B | Forward | CGAATCGCCGTGAAGAAAGC |
| Reverse | CTTGCAGGCGGAGTACACT | |
| CCNG2 | Forward | TAGCAGGGACAGTGGATA |
| Reverse | AATACTTGGGCAATAGGA | |
| GAPDH | Forward | TGACAACTTTGGTATCGTGGAAGG |
| Reverse | AGGCAGGGATGATGTTCTGGAGAG |
Fig 2Box diagram after data preprocessing (A), volcano plot (B) heatmap diagram (C), and principal component analysis (PCA) plots (D) of gene expression profiles. Green arethe AIS samples, and yellow are the control samples
KEGG pathway and Gene Ontology (GO)‐Biological Process (BP) analysis results of differentially expressed genes (DEGs)
| ID | Name | Count |
| Gene | |
|---|---|---|---|---|---|
| Up‐regulated genes | |||||
| Pathway | hsa04115 | p53 signaling pathway | 3 | 3.04E‐03 | DDB2;STEAP3;CCNG2 |
| hsa04068 | FoxO signaling pathway | 3 | 1.84E‐02 | FBXO32;RBL2;CCNG2 | |
| hsa04022 | cGMP‐PKG signaling pathway | 3 | 3.64E‐02 | GTF2I;PRKG1;PDE5A | |
| GO‐BP | GO:0006357 | regulation of transcription from RNA polymerase II promoter | 8 | 4.06E‐03 | CAMTA2, TSHZ1, ANKRA2, RBL2, GTF2I, TFDP2, VEZF1, BRD8 |
| GO:0006633 | fatty acid biosynthetic process | 3 | 2.37E‐02 | ELOVL4, FAXDC2, CBR4 | |
| GO:0006091 | generation of precursor metabolites and energy | 3 | 2.46E‐02 | FECH, SLC25A27, DHTKD1 | |
| GO:0007264 | small GTPase mediated signal transduction | 5 | 2.65E‐02 | PLD2, RASL11A, ARL17A, RALBP1, DOCK11 | |
| GO:0007165 | signal transduction | 11 | 3.88E‐02 | RAP2B, RALBP1, GTF2I, PPP2R5D, PKIG, PDE5A, MCC, PRKG1, BRD8, DAPK1, DTNA | |
| Down‐regulated genes | |||||
| Pathway | hsa04141 | Protein processing in endoplasmic reticulum | 4 | 2.78E‐03 | ERO1A;STT3A;DERL1;TXNDC5 |
| hsa05020 | Prion diseases | 2 | 7.98E‐03 | LAMC1;MAP2K1 | |
| hsa05110 | Vibrio cholerae infection | 2 | 1.58E‐02 | KDELR2;ERO1A | |
| hsa00510 | N‐Glycan biosynthesis | 2 | 1.64E‐02 | STT3A;MGAT5 | |
| hsa00590 | Arachidonic acid metabolism | 2 | 2.20E‐02 | PTGS1;CBR1 | |
| hsa04610 | Complement and coagulation cascades | 2 | 3.24E‐02 | A2M;MBL2 | |
| hsa05222 | Small cell lung cancer | 2 | 4.25E‐02 | LAMC1;TRAF3 | |
| GO‐BP | GO:0006457 | protein folding | 4 | 2.65E‐02 | GRPEL1, ERO1A, TXNDC5, PDIA6 |
| GO:0034976 | response to endoplasmic reticulum stress | 3 | 2.95E‐02 | ERO1A, TXNDC5, PDIA6 | |
| GO:0022617 | extracellular matrix disassembly | 3 | 3.02E‐02 | A2M, LAMC1, CTSG | |
| GO:0045454 | cell redox homeostasis | 3 | 3.10E‐02 | ERO1A, TXNDC5, PDIA6 | |
| GO:0019371 | cyclooxygenase pathway | 2 | 3.52E‐02 | CBR1, PTGS1 | |
| GO:0034975 | protein folding in endoplasmic reticulum | 2 | 4.55E‐02 | ERO1A, EMC1 | |
Fig 3Theprotein‐protein interaction (PPI)networkof differentially expressed genes in AIS (A).Thesignificant clustering modules of the PPI network (B). The circle nodes indicate the up‐regulated genes, and the diamond nodes represent the down‐regulated genes.
KEGG pathway enriched by differentially expressed genes (DEGs) in the sub‐network module
| ID | Name | Count |
| Genes |
|---|---|---|---|---|
| hsa04068 | FoxO signaling pathway | 3 | 2.17E‐04 | MAP2K1;RBL2;CCNG2 |
| hsa04730 | Long‐term depression | 2 | 1.53E‐03 | PRKG1;MAP2K1 |
| hsa04540 | Gap junction | 2 | 3.45E‐03 | PRKG1;MAP2K1 |
| hsa04270 | Vascular smooth muscle contraction | 2 | 5.98E‐03 | PRKG1;MAP2K1 |
| hsa04919 | Thyroid hormone signaling pathway | 2 | 6.09E‐03 | MAP2K1;KAT2B |
| hsa04022 | cGMP‐PKG signaling pathway | 2 | 1.16E‐02 | PRKG1;MAP2K1 |
| hsa05203 | Viral carcinogenesis | 2 | 1.50E‐02 | RBL2;KAT2B |
| hsa04010 | MAPK signaling pathway | 2 | 2.53E‐02 | DUSP6;MAP2K1 |
| hsa04151 | PI3K‐Akt signaling pathway | 2 | 4.45E‐02 | MAP2K1;RBL2 |
Fig 4The microRNA‐transcription factor‐Target regulatory network. The triangle nodesaremiRNAs, the hexagon nodesare transcription factors, and edges with an arrow indicate regulatory relationships.
Fig 5The qRT‐PCR analysis of five crucial genes, including MAP2K1, PRKG1, KAT2B, CCNG2 and DUP6.Data were expressed as mean ± standard deviation. Comparisons between groups were calculated by student's t test. *, P < 0.05; **, P < 0.01***, P < 0.001.
Fig 6The protein expression of PRKG1 detected by immunohistochemicalanalysis (×200). The arrow indicatesPRKG1 expression.